Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Keros Therapeutics
Biotech
Keros halts 2 arms of hypertension trial over fluid near heart
Keros has halted dosing in two arms of a phase 2 trial of its pulmonary arterial hypertension drug over reports of fluid buildups around the heart.
James Waldron
Dec 12, 2024 6:30am
Takeda pays Keros $200M upfront for rival to BMS' Reblozyl
Dec 3, 2024 7:30am
Marea, Ashibio, Arvinas & more—Chutes & Ladders
Jun 21, 2024 8:30am
Bayer undergoes leadership shake-up—Chutes & Ladders
Mar 22, 2024 9:30am
Keros upsizes IPO, raising $96M for midphase trials
Apr 8, 2020 8:00am
